Reykjavik

• Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) Not authorised
  2023-503969-36-00 4 Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
• A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active convent … Pending
  2024-516723-14-00 6 Rheumatoid Arthritis
• Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple my … Pending
  2024-519353-11-00 4 Multiple Myeloma
• A Randomized, Non-inferiority Trial Comparing 7-Day Versus 4-Week Esomeprazole Treatment in Patients with Unexplained Dyspepsia Pending
  2025-524044-35-00 6 Dyspepsia
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• The Intensive Care Platform Trial (INCEPT) Recruiting
  2024-516208-41-00 6 2025-06-26 Acute critical illness requiring intensive care unit admission.
• Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer Recruiting
  2022-502221-18-00 6 2025-05-26 Recurrent non-muscle invasive bladder cancer
• CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit … Recruiting
  2023-505000-27-01 4 2023-12-29 newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML
• Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects with Alzheimer’s Disease (AD) Recruiting
  2024-519497-39-00 4 2025-10-03 Alzheimer's Disease
• Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 … Recruiting
  2023-508196-36-00 4 2025-05-27 Follicular lymphoma
• CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting
  2023-504999-25-00 5 2023-07-14 Acute Myeloid Leukemia
• SACK Recruiting
  2022-501600-10-00 5 2023-02-07 Atrial fibrillation and Chronic Kidney Disease stage 5
• Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten (CK-3773274) in Adults With Hypertrophic Cardiomyo … Recruiting
  2023-508963-58-00 4 2022-01-31 Symptomatic hypertrophic cardiomyopathy (HCM)
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting
  2022-501050-11-01 10 2020-07-13 Acute Lymphoblastic Leukaemia
• Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) Ended recruitment
  2023-503969-36-01 4 2024-03-26 Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
• Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with exten … Ended recruitment
  2023-505514-15-00 5 2022-01-11 Small-cell lung cancer, extensive stage
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• Vaginal progesterone as luteal support for improvement of live birth in frozen/thawed in-vitro fertilization natural cycles; a multicenter, … Ended recruitment
  2024-512844-40-00 6 2021-04-20 Infertility
• NORTH-REG Dwell-Time Study Ended recruitment
  2023-505936-37-00 6 2021-02-03 Urothelial cancer
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in pati … Ended recruitment
  2023-508551-40-00 6 2018-06-08 Coronary artery multi-vessel disease and left main stenosis
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with locally advanced or metastatic KRAS G12C mutant non … Halted
  2023-510082-10-00 5 2022-09-05 Advanced non-small cell lung cancer harboring the KRAS G12C mutation
• A study of aficamten (CK-3773274) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (ACACIA) Ended
  2023-505797-15-00 5 2024-09-13 SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

Showing 1–24 of 26 trials